Inogen, Inc (INGN) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inogen, Inc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.279 excellent job strengthening relationships with DMEs and winning tenders internationally. 00:00:05.279 -- 00:00:09.765 These results bolster our confidence in our total market approach and the strength of 00:00:09.765 -- 00:00:14.712 the image of brands. Turning to our second priority, driving profitability, where we 00:00:14.712 -- 00:00:19.623 continued to advance through operational excellence and disciplined cost management. 00:00:19.623 -- 00:00:23.990 In the second quarter, we delivered meaningful operating leverage, reducing operating 00:00:23.990 -- 00:00:29.337 expenses by approximately 5% year-over-year and generating $2.1 million 00:00:29.337 -- 00:00:35.467 in adjusted EBITDA. This is our second consecutive quarter of adjusted EBITDA profitability. 00:00:35.467 -- 00:00:40.574 It also marks the fourth adjusted EBITDA profitable quarter out of the last five, 00:00:40.574 -- 00:00:45.678 highlighting consistent execution of our strategies in disciplined expense management. 00:00:45.678 -- 00:00:50.846 As a result, we now expect to achieve full year adjusted EBITDA breakeven 00:00:50.846 -- 00:00:56.615 in 2025, supported by sustained revenue growth and disciplined spending. 00:00:56.615 -- 00:01:01.543 We remain focused on driving further improvement in the coming years as we advance towards 00:01:01.543 -- 00:01:03.987 sustainable profitability. 00:01:03.987 -- 00:01:08.554 We continued to advance our innovation pipeline this quarter with meaningful progress 00:01:08.554 -- 00:01:13.613 across our key strategic priorities. We introduced BOXY5, our latest 00:01:13.613 -- 00:01:18.918 stationary oxygen concentrator designed to expand access to high-quality therapy 00:01:18.918 -- 00:01:21.400 for long-term care patients. 00...